Global Information
회사소개 | 문의

심장 페이싱/이식형 제세동기(ICD) 리드 : 의료기기 파이프라인 평가

Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Medical Devices Pipeline Assessment, 2018

리서치사 GlobalData
발행일 2018년 06월 상품 코드 361018
페이지 정보 영문 107 Pages
가격
US $ 2,500 ₩ 2,858,500 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,717,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,575,500 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심장 페이싱/이식형 제세동기(ICD) 리드 : 의료기기 파이프라인 평가 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Medical Devices Pipeline Assessment, 2018
발행일 : 2018년 06월 페이지 정보 : 영문 107 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계 심장 페이싱(Cardiovascular Pacing) 및 이식형 제세동기(ICD) 리드 시장의 주요 파이프라인 제품과 임상시험 진행 상황에 대해 조사했으며, 제품의 기능 및 특성 비교 분석(임상시험 진행 단계별), 주요 기업 개요 및 대표적 제품, 최근의 시장 동향(실적 보고 및 자본 거래 동향 등) 등의 정보를 전해드립니다.

제1장 목차

제2장 서론

  • 심장 페이싱/ICD 리드 개요

제3장 임상시험중인 제품

  • 파이프라인 제품 : 임상시험 단계별
  • 파이프라인 제품 : 지역별
  • 파이프라인 제품 : 규제 경로별
  • 파이프라인 제품 : 추정 인증 시기별
  • 현재 진행중인 임상시험

제4장 임상시험중인 파이프라인 제품 : 기업별

  • 심장 페이싱/ICD 리드 기업 : 임상시험 단계별 파이프라인 제품
  • 심장 페이싱/ICD 리드 : 임상시험 단계별 파이프라인 제품

제5장 심장 페이싱/ICD 리드 : 기업 및 제품 개요

  • Boston Scientific Corporation
    • 파이프라인 제품 및 진행중인 임상시험 개요
  • Imricor Medical Systems, Inc.
  • LivaNova PLC
  • Mayo Clinic US
  • Medtronic plc
  • MicroPort Scientific Corporation
  • MRI Interventions, Inc
  • St. Jude Medical, Inc.
  • Teleflex Incorporated

제6장 심장 페이싱/ICD 리드 : 최근 시장 동향(총 34건)

제7장 부록

도표

LSH 16.07.08

List of Tables

1.1 List of Tables

  • Table 1: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Stage of Development 8
  • Table 2: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Territory 9
  • Table 3: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Regulatory Path 10
  • Table 4: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Estimated Approval Date 11
  • Table 5: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Ongoing Clinical Trials 12
  • Table 6: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads Companies - Pipeline Products by Stage of Development 13
  • Table 7: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Stage of Development 14
  • Table 8: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 9: Acuity X4 Quad LV Lead - 1.5T MRI - Product Status 15
  • Table 10: Acuity X4 Quad LV Lead - 1.5T MRI - Product Description 16
  • Table 11: Acuity X4 Quad LV Lead - 3T MRI - Product Status 16
  • Table 12: Acuity X4 Quad LV Lead - 3T MRI - Product Description 16
  • Table 13: MRI-Safe Implantable Cardiac Rhythm Management Lead - Product Status 17
  • Table 14: MRI-Safe Implantable Cardiac Rhythm Management Lead - Product Description 17
  • Table 15: Next Generation ICD Lead - Product Status 17
  • Table 16: Next Generation ICD Lead - Product Description 18
  • Table 17: Reliance 4-Front Lead - Product Status 18
  • Table 18: Reliance 4-Front Lead - Product Description 18
  • Table 19: X4 SYSTEM + QUAD LEAD - Product Status 19
  • Table 20: X4 SYSTEM + QUAD LEAD - Product Description 19
  • Table 21: Boston Scientific Corp - Ongoing Clinical Trials Overview 20
  • Table 22: Reliance 4-Front Lead - Evaluation of Acuity X4 Quadripolar Coronary Venous Leads and Reliance 4-Front Defibrillation Leads: NAVIGATE X4 21
  • Table 23: Reliance 4-Front Lead - Expanding MRI Access for Patients with New and Existing ICDs and CRT-Ds: ENABLE MRI 21
  • Table 24: Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 25: Magnetic Resonance Imaging (MRI) Compatible Lead - Product Status 22
  • Table 26: Magnetic Resonance Imaging (MRI) Compatible Lead - Product Description 22
  • Table 27: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 28: Beflex Brady Lead - Product Status 23
  • Table 29: Beflex Brady Lead - Product Description 24
  • Table 30: Nano Lead System - Product Status 24
  • Table 31: Nano Lead System - Product Description 24
  • Table 32: SonR Tist Lead Positioning - Product Status 24
  • Table 33: SonR Tist Lead Positioning - Product Description 25
  • Table 34: SonRFix Lead - Product Status 25
  • Table 35: SonRFix Lead - Product Description 25
  • Table 36: Tachy Lead - Product Status 26
  • Table 37: Tachy Lead - Product Description 26
  • Table 38: TX Brady Lead - Product Status 26
  • Table 39: TX Brady Lead - Product Description 26
  • Table 40: Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 41: Pacemaker/ICD Lead - Product Status 27
  • Table 42: Pacemaker/ICD Lead - Product Description 27
  • Table 43: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 44: Attain Stability Quad MRI SureScan - Product Status 28
  • Table 45: Attain Stability Quad MRI SureScan - Product Description 28
  • Table 46: Medtronic plc - Ongoing Clinical Trials Overview 29
  • Table 47: Attain Stability Quad MRI SureScan - Attain Stability Quad Clinical Study 30
  • Table 48: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 49: BonaFire - Active Pacing Lead - Product Status 31
  • Table 50: BonaFire - Active Pacing Lead - Product Description 31
  • Table 51: BonaFire - Passive Pacing Lead - Product Status 32
  • Table 52: BonaFire - Passive Pacing Lead - Product Description 32
  • Table 53: St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 54: Quartet NXT - Double Blend Lead - Product Status 33
  • Table 55: Quartet NXT - Double Blend Lead - Product Description 33
  • Table 56: Quartet NXT - Large S-Curve Lead - Product Status 34
  • Table 57: Quartet NXT - Large S-Curve Lead - Product Description 34
  • Table 58: Quartet NXT - Small S-Curve Lead - Product Status 34
  • Table 59: Quartet NXT - Small S-Curve Lead - Product Description 35
  • Table 60: Quartet Quadripolar LV Lead - MRI Labelling - Product Status 35
  • Table 61: Quartet Quadripolar LV Lead - MRI Labelling - Product Description 35
  • Table 62: Teleflex Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 63: Pacemaker Lead - Product Status 36
  • Table 64: Pacemaker Lead - Product Description 36
  • Table 65: Glossary 106

List of Figures

1.2 List of Figures

  • Figure 1: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Stage of Development 8
  • Figure 2: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Territory 9
  • Figure 3: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Regulatory Path 10
  • Figure 4: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Estimated Approval Date 11
  • Figure 5: Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Ongoing Clinical Trials 12

영문목차

GlobalData's Medical Devices sector report, "Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Medical Devices Pipeline Assessment, 2018" provides an overview of Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads Overview 7

3 Products under Development 8

  • 3.1 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Stage of Development 8
  • 3.2 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Territory 9
  • 3.3 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Regulatory Path 10
  • 3.4 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Estimated Approval Date 11
  • 3.5 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Ongoing Clinical Trials 12

4 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products under Development by Companies 13

  • 4.1 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads Companies - Pipeline Products by Stage of Development 13
  • 4.2 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads - Pipeline Products by Stage of Development 14

5 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads Companies and Product Overview 15

  • 5.1 Boston Scientific Corp Company Overview 15
    • 5.1.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.2 Imricor Medical Systems Inc Company Overview 22
    • 5.2.1 Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.3 LivaNova PLC Company Overview 23
    • 5.3.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.4 Mayo Clinic Company Overview 27
    • 5.4.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.5 Medtronic plc Company Overview 28
    • 5.5.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.6 MicroPort Scientific Corp Company Overview 31
    • 5.6.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.7 St. Jude Medical LLC Company Overview 33
    • 5.7.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.8 Teleflex Inc Company Overview 36
    • 5.8.1 Teleflex Inc Pipeline Products & Ongoing Clinical Trials Overview 36

6 Cardiovascular Pacing and Implantable Cardioverter-Defibrillator (ICD) Leads- Recent Developments 37

  • 6.1 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 37
  • 6.2 May 15, 2018: MRI Interventions Announces First Quarter 2018 Results 37
  • 6.3 May 08, 2018: T2 Biosystems Announces First Quarter 2018 Financial Results 39
  • 6.4 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 40
  • 6.5 May 03, 2018: Integer Holdings Reports First Quarter 2018 Results 41
  • 6.6 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 42
  • 6.7 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 44
  • 6.8 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results 45
  • 6.9 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results 47
  • 6.10 Mar 15, 2018: MRI Interventions Reports 34% Year-Over-Year Increase in Functional Neurology Revenues, 50% increase in Capital Sales 47
  • 6.11 Mar 06, 2018: T2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business Update 50
  • 6.12 Mar 01, 2018: Safety and Effectiveness of BioTrace Medical's Tempo Lead Further Demonstrated in Multi-Center Analysis of More Than 200 Cardiac Procedures 51
  • 6.13 Feb 28, 2018: LivaNova Announces Fourth Quarter and Full-Year 2017 Results 52
  • 6.14 Feb 22, 2018: Integer Holdings Reports Results for Fourth Quarter and Full Year 2017 54
  • 6.15 Feb 22, 2018: Integer Announces Strategy Focused on Portfolio Management and Operational Excellence; Aligns Senior Management to Execute Strategic Imperatives 56
  • 6.16 Feb 12, 2018: Integer Elects James Hinrichs to its Board of Directors 57
  • 6.17 Feb 07, 2018: Caisson Interventional Expanding in Maple Grove 57
  • 6.18 Feb 06, 2018: MRI Interventions Announces Record 629 ClearPoint Cases in 2017 58
  • 6.19 Feb 05, 2018: T2 Biosystems Names John Sprague As CFO 59
  • 6.20 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 59
  • 6.21 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 61
  • 6.22 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 62
  • 6.23 Jan 08, 2018: LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development 62
  • 6.24 Jan 02, 2018: Integer Names Kirk Thor Chief Human Resources Officer 63
  • 6.25 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 63
  • 6.26 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 64
  • 6.27 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 67
  • 6.28 Nov 06, 2017: MRI Interventions Reports 26% Year-Over-Year Increase in Third Quarter Procedures 68
  • 6.29 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 71
  • 6.30 Nov 02, 2017: T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update 72
  • 6.31 Nov 02, 2017: LivaNova Reports Third Quarter 2017 Results 73
  • 6.32 Oct 26, 2017: BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2017 75
  • 6.33 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 76
  • 6.34 Oct 26, 2017: Integer Holdings Reports Third Quarter 2017 Results 78
  • 6.35 Oct 09, 2017: MRI Interventions Announces Joseph Burnett As New President and CEO 79
  • 6.36 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 80
  • 6.37 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 81
  • 6.38 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY 82
  • 6.39 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 83
  • 6.40 Aug 21, 2017: Medtronic Receives CE Mark for Attain Stability Quad MRI SureScan Active-Fixation Heart Lead 86
  • 6.41 Aug 15, 2017: T2 Biosystems and Aridis Pharmaceuticals Join Antimicrobials Working Group 87
  • 6.42 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 87
  • 6.43 Aug 09, 2017: LivaNova Reports Second Quarter 2017 Results 88
  • 6.44 Aug 03, 2017: T2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update 89
  • 6.45 Aug 03, 2017: Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million 90
  • 6.46 Aug 01, 2017: MRI Interventions Reports 79% Revenue Increase and Record Treatments in Second Quarter 2017 91
  • 6.47 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 93
  • 6.48 Jul 27, 2017: Integer Holdings Reports Second Quarter 2017 Results 95
  • 6.49 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 96
  • 6.50 Jul 17, 2017: Integer Announces Appointment of Joseph W. Dziedzic as President and Chief Executive Officer 97
  • 6.51 Jul 11, 2017: MRI Interventions Announces Record Second Quarter ClearPoint System Procedures, And a 79% Year-Over-Year Revenue Increase 97
  • 6.52 Jul 07, 2017: MPSC New COO Glendy Wang on Board 98
  • 6.53 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 98
  • 6.54 Jun 19, 2017: BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance Consistent with Clinical Study Outcomes In TVT 2017 Presentation 100
  • 6.55 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors 101
  • 6.56 Jun 12, 2017: LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel 102
  • 6.57 Jun 08, 2017: BioTrace Medical Announces Key Activities at TVT 2017 102

7 Appendix 104

  • 7.1 Methodology 104
  • 7.2 About GlobalData 107
  • 7.3 Contact Us 107
  • 7.4 Disclaimer 107
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research